Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M von Mehren

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Monoclonal antibodies in cancer treatment: a review of recent progressK Alpaugh, M von Mehren
Current Opinion in Oncology|November 1, 1996
Monoclonal antibody-based therapyM von Mehren, L M Weiner
Cancer Immunology, Immunotherapy : CII|January 22, 1998
Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteinsL M Weiner, R K Alpaugh, M von Mehren
Seminars in Oncology Nursing|January 11, 2001
Recent advances in immunotherapy and monoclonal antibody treatment of cancerJ D Cheng, P T Rieger, M von Mehren, et al.
Investigational New Drugs|January 1, 1995
Phase I trial of ilmofosine as a 24 hour infusion weeklyM von Mehren, B J Giantonio, C McAleer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practicesP W T Pisters, C D Blanke, M von Mehren, et al.
Cancer Chemotherapy and Pharmacology|November 29, 2011
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinibC Cauchi, N Somaiah, P F Engstrom, et al.
Medical Oncology (Northwood, London, England)|November 20, 1998
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferonR K Alpaugh, M von Mehren, I Palazzo, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1997
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatmentJ I Clark, R K Alpaugh, M von Mehren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2012
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomasM Agulnik, J L Yarber, S H Okuno, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Monoclonal antibodies in cancer treatment: a review of recent progressK Alpaugh, M von Mehren
Current Opinion in Oncology|November 1, 1996
Monoclonal antibody-based therapyM von Mehren, L M Weiner
Cancer Immunology, Immunotherapy : CII|January 22, 1998
Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteinsL M Weiner, R K Alpaugh, M von Mehren
Seminars in Oncology Nursing|January 11, 2001
Recent advances in immunotherapy and monoclonal antibody treatment of cancerJ D Cheng, P T Rieger, M von Mehren, et al.
Investigational New Drugs|January 1, 1995
Phase I trial of ilmofosine as a 24 hour infusion weeklyM von Mehren, B J Giantonio, C McAleer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practicesP W T Pisters, C D Blanke, M von Mehren, et al.
Cancer Chemotherapy and Pharmacology|November 29, 2011
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinibC Cauchi, N Somaiah, P F Engstrom, et al.
Medical Oncology (Northwood, London, England)|November 20, 1998
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferonR K Alpaugh, M von Mehren, I Palazzo, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1997
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatmentJ I Clark, R K Alpaugh, M von Mehren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2012
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomasM Agulnik, J L Yarber, S H Okuno, et al.
Pageof 3